Aurobindo Pharma Unit Partners With MSD For Contract Manufacturing Venture

Aurobindo Pharma Ltd. on Friday said its unit TheraNym Biologics has inked a pact with MSD to set up a plant as it looks to enter the contract manufacturing operations for biologicals. TheraNym Biologics, a wholly-owned subsidiary of Aurobindo Pharma and an affiliate of CuraTeQ, has inked a Master Service Agreement (MSA) with MSD effective today.

As part of the arrangement, Theranym will invest around Rs 1,000 crore for establishing manufacturing facility with capacity of up to 25-30 million vials per annum, the Hyderabad-based drug firm said in a regulatory filing.

TheraNym will build the manufacturing facility, manufacture the products and supply to MSD as per the arrangement, it added.

Last year in October, CuraTeQ Biologics and Merck Sharp & Dohme Singapore Trading Pte Ltd and its affiliates (MSD) had signed a letter of intent for contract manufacturing operations for biologicals, whereby the parties intended to conclude the negotiations by March 31, 2024.

The partes later extended the deadline till May 31.